EVALUATİON OF E-CADHERİN , MMP-2 İN COLORECTAL CARCİNOMA

Hilal Erinanç, Emin Turk

Abstract


Background : Colorectal cancer pogression is a multistep process, in which many genes and proteins
are involved. Matrix metalloproteinase and loss of-E-Cadherin has been considered to be associated
with cancer invasion and metastasis. In our study, we aim to evaluate the expressions of E-Cadherin and MMP-2 in colorectal
carcinoma .
Material and Methods: Expressions of E- Cadherin and MMP-2 in specimens from 48 colorectal adenocarcinomas ( 24 classic
adenocarcinomas and 24 mucinous adenocarcinomas) were detected by immunohistochemistry.
Results: MMP-2 expression was found 45,84% in classic adenocarcinoma while E-Cadherin was found 33,33% in mucinous
carcinomas.
Conclusion: Our ndings demonstrate that E-cadherin and MMP-2 expression contributes to tumor development. It sems that
MMP-2 expression was more associated with classic adenocarcinomas while E-Cadherin was related with mucinous
adenocarcinomas .Further studies are need to nd the correlations between E-cadherin ,MMP-2 and epithelial-mesenchymal
transition.


Keywords


colorectal cancer, E-Cadherin, MMP-2

Full Text:

PDF

References


-Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2017 Feb;65(2):311-315.

- Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011 Jan;278(1):16-27.

- Hua H., Li M., Luo T., Yin Y., Jiang Y. Matrix metalloproteinases in tumorigenesis: An evolving paradigm. Cell. Mol. Life Sci. 2011;68:3853–3868

-Salem N, Kamal I, Al-Maghrabi J, Abuzenadah A, Peer-Zada AA, Qari Y, Al-Ahwal M, Al-Qahtani M, Buhmeida A. High expression of matrix metalloproteinases: MMP-2 and MMP-9 predicts poor survival outcome in colorectal carcinoma. Future Oncol. 2016;12(3):323-331.

-Langenskiold M., Holmdahl L., Falk P., Ivarsson M.L. Increased plasma mmp-2 protein expression in lymph node-positive patients with colorectal cancer. Int. J. Colorectal Dis. 2005;20:245–252

- Hong SW, Kang YK, Lee B, Lee WY, Jang YG, Paik IW, Lee H Matrix metalloproteinase-2 and -7 expression in colorectal cancer. J Korean Soc Coloproctol. 2011 ;3:133-139.

- Canel M, Serrels A, Frame MC, Brunton VG. E-cadherin-integrin crosstalk in cancer invasion and metastasisJ Cell Sci. 2013 ;126:393-401.

- Clevers H Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.

-Scholer-Dahirel A, Schlabach MR, Loo A, et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci USA. 2011;108:17135–17140

- Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity. 2007; 26: 227‐ 239.

-Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008 Nov-Dec;28(6A):3815-26.

-Christou N, Perraud A, Blondy S, Jauberteau MO, Battu S, Mathonnet M E-cadherin: A potential biomarker of colorectal cancer prognosisOncol Lett. 2017 Jun;13(6):4571-4576.

- Fred T bomsan, Fatime Carneiro, Ralph H. Hruban , Noil D. Theise WHO Classification of Tumors of the Digestive System IARC: Lyon 2010

-Adachi Y., Yamamoto H., Itoh F., Hinoda Y., Okada Y., Imai K. Contribution of matrilysin (mmp-7) to the metastatic pathway of human colorectal cancers. Gut. 1999;45:252–258

- Dragutinovic V.V., Radonjic N.V., Petronijevic N.D., Tatic S.B., Dimitrijevic I.B., Radovanovic N.S., Krivokapic Z.V. Matrix metalloproteinase-2 (mmp-2) and -9 (mmp-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer. Mol. Cell. Biochem. 2011;355:173–178.

- Sunami E., Tsuno N., Osada T., Saito S., Kitayama J., Tomozawa S., Tsuruo T., Shibata Y., Muto T., Nagawa H. Mmp-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;5:108–114

- Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700–10.

-Wong JC, Chan SK, Schaeffer DF, Sagaert X, Lim HJ, Kennecke H, Owen DA, Suh KW, Kim YB, Tai IT. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer Clin Cancer Res. 2011 Jun 15;17(12):4167-76

- Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157–66.

- Groblewska M, Mroczko B, Gryko M, Pryczynicz A, Guzińska-Ustymowicz K, Kędra B, Kemona A, Szmitkowski M. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumour Biol. 2014; 35(4):3793-802.

-Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira

J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis

CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, Oliveira C,

Seruca R. Epithelial E- and P-cadherins: role and clinical significance in cancer.

Biochim Biophys Acta. 2012;1826(2):297–311.

-. Wijnhoven BP, Dinjens WN and Pignatelli M: E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000; 87: 992–1005.

-. Chao YL, Shepard CR and Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 179, .

-. Bae K-M, Parker NN, Dai Y, Vieweg J and Siemann DW: E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res 2011; 1: 71–84.

- He, X.; Chen, Z.; Jia, M.; Zhao, X. Downregulated E-Cadherin Expression Indicates Worse Prognosis in Asian Patients with Colorectal Cancer: Evidence from Meta-Analysis. PLoS ONE 2013, 8, e70858

- Karamitopoulou, E.; Zlobec, I.; Patsouris, E.; Peros, G.; Lugli, A. Loss of E-Cadherin Independently Predicts

the Lymph Node Status in Colorectal Cancer. Pathology 2011; 43, 133–137.

- Tóth, L.; András, C.; Molnár, C.; Tanyi, M.; Csiki, Z.; Molnár, P.; Szántó, J. Investigation of _-Catenin and E-Cadherin Expression in Dukes B2 Stage Colorectal Cancer with Tissue Microarray Method. Is It a Marker of Metastatic Potential in Rectal Cancer? Pathol. Oncol. Res. POR 2012; 18, 429–437.

- Khoursheed, M.A.; Mathew, T.C.; Makar, R.R.; Louis, S.; Asfar, S.K.; Al-Sayer, H.M.; Dashti, H.M.; Al-Bader, A. Expression of E-Cadherin in Human Colorectal Cancer. Surg. J. R. Coll. Surg. Edinb. Irel. 2003; 1, 86–91

- Weiss, J.V.; Klein-Scory, S.; Kübler, S.; Reinacher-Schick, A.; Stricker, I.; Schmiegel, W.; Schwarte-Waldho, I.Soluble E-Cadherin as a Serum Biomarker Candidate: Elevated Levels in Patients with Late-Stage Colorectal Carcinoma and FAP. Int. J. Cancer 2011; 128, 1384–1392

- Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci. 2001;J14(Pt 1):111-118.

-Nowak M, Madej JA, Pula B, Dziegiel P, Ciaputa R.Expression of matrix metalloproteinase 2 (MMP-2), E-cadherin and Ki-67 in metastatic and non-metastatic canine mammary carcinomas. Ir Vet J. 2016 Aug 2;69:9.

- Cong Luo, Shuyi Cen, Guojun Ding, and Wei Wu Mucinous colorectal adenocarcinoma: clinical pathology and treatment optionsCancer Commun (Lond). 2019; 39: 13.


Refbacks

  • There are currently no refbacks.